+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Hypothalamic Infusion of Activin A Increases Water Consumption and Urine Volume in the Rat

      , ,


      S. Karger AG

      Activin, Hypothalamus, Water consumption, Urine volume, Fluid balance

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Activin A immunoreactivity has been localized within the nucleus tractus solitarius and its projections into regions of the hypothalamus such as the para-ventricular nucleus. However, the function of activin within the central nervous system is unclear. Because these regions of the brain are involved in the regulation of a variety of metabolic processes, we have measured body weight, food and water consumption, fecal mass, and urine volume in adult rats that received bilateral infusions of activin A into the dorsal hypothalamus near the paraventricular nuclei. Activin caused marked, parallel increases in water consumption and urine volume that were first apparent on days 3-4 and were maintained for the duration of the week-long infusions. There was no effect on water consumption or urine volume when the same doses of inhibin A or cytochrome c were infused, indicating that the effects of activin were specific and not due simply to infusion of protein into the hypothalamus. Furthermore, the effects of activin were selective for water consumption and urine volume, as neither activin, inhibin, nor cytochrome c had any effect on weight gain, food consumption, or fecal mass. Our results demonstrate that an activin A-containing neuronal system within the hypothalamus may have a role in the central regulation of fluid balance.

          Related collections

          Author and article information

          S. Karger AG
          08 April 2008
          : 57
          : 3
          : 510-516
          Department of Endocrine Research, Genentech, Inc., South San Francisco, Calif., USA
          126399 Neuroendocrinology 1993;57:510–516
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article